Core Viewpoint - The medical device sector experienced a rise of 1.42% on February 3, with Huakang Clean leading the gains, while the overall market indices also showed positive performance [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4067.74, up by 1.29% [1]. - The Shenzhen Component Index closed at 14127.1, up by 2.19% [1]. Group 2: Top Gainers in Medical Device Sector - Huakang Clean (301235) closed at 53.83, with a gain of 9.86% and a trading volume of 114,200 shares, amounting to a transaction value of 610 million yuan [1]. - Baocait (300246) closed at 13.15, up by 7.96% with a trading volume of 178,500 shares, totaling 229 million yuan [1]. - Yirui Technology (688301) closed at 119.24, increasing by 7.10% with a trading volume of 41,000 shares, resulting in a transaction value of 477 million yuan [1]. - Hualan Co. (301093) closed at 86.08, up by 6.45% with a trading volume of 60,900 shares, totaling 482 million yuan [1]. - Tianzhihang (688277) closed at 24.18, increasing by 6.10% with a trading volume of 159,300 shares, amounting to 379 million yuan [1]. Group 3: Market Outflows and Inflows - The medical device sector saw a net outflow of 253 million yuan from institutional investors and a net outflow of 112 million yuan from speculative funds, while retail investors had a net inflow of 365 million yuan [2]. - The detailed fund flow for individual stocks indicates varying levels of net inflow and outflow among different companies [3].

（编辑 任世碧） 证券日报网讯 2月2日，华兰股份发布公告称，截至2026年1月31日，公司通过回购专用证券账户以集中 竞价交易方式累计回购公司股份数量为2，975，699股，占公司目前总股本的1.81%。 ...

证券代码：301093 证券简称：华兰股份 公告编号：2026-010 江苏华兰药用新材料股份有限公司 会及深圳证券交易所相关法律法规要求相应调整回购价格上限。 公司 2024 年年度权益分派实施后，公司使用超募资金、自有资金及自筹资 金以集中竞价交易方式回购股份的价格上限由不超过人民币 45.50 元/股（含） 调整为不超过人民币 34.84 元/股（含）。公司本次对回购股份价格上限进行调整， 自 2025 年 7 月 14 日起生效。具体内容详见公司于 2025 年 7 月 15 日在巨潮资 讯网（www.cninfo.com.cn）上披露的《关于 2024 年年度权益分派实施后调整回 购股份价格上限的公告》。 注：上表中的回购数量是以调整后的回购价格上限 34.84 元/股进行测算，以上合计数据与 各明细数据相加之和在尾数上如有差异是由于四舍五入所造成。具体回购股份数量以回购 完毕或回购实施期限届满时实际回购的股份数量为准。 一、公司回购股份的进展情况 关于使用超募资金、自有资金及自筹资金以集中竞价交易方式 回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载 ...

华兰股份公告，控股股东江阴华兰机电科技有限公司于2026.01.29质押170万股，占其持股4.62%、占公 司总股本1.04%，质权人为中国农业银行股份有限公司江阴分行，质押用途为二级市场证券投资(增持公 司股份)。本次后控股股东及一致行动人累计质押股份170万股，占所持股份3.43%、占公司总股本 1.04%。 ...

每经头条（nbdtoutiao）——核电建设热潮下，设备厂忙到"飞起"！订单已排至2028年，员工三班倒， 产线24小时不停 每经AI快讯，华兰股份1月30日晚间发布公告称，截至本公告日，江阴华兰机电科技有限公司累计质押 股数为170万股，占其所持股份比例为4.62%。 （记者 曾健辉） ...

证券代码：301093 证券简称：华兰股份 公告编号：2026-009 江苏华兰药用新材料股份有限公司 关于控股股东质押部分股份的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 江苏华兰药用新材料股份有限公司（以下简称"公司"或"华兰股份"）于 近日收到了控股股东江阴华兰机电科技有限公司（以下简称"华兰机电"）出具 的《关于股份质押的告知函》以及中国证券登记结算有限责任公司出具的《证 券质押登记证明》《证券质押及司法冻结明细表》，获悉华兰机电将其所持有的 部分公司股份办理了质押业务，相关质押登记手续已办理完毕，具体情况如下： 一、 股东股份质押基本情况 | 股东 | 是否为 控股股 东或第 | 本次质押 | 占其所 | 占公 司总 | 是否为 | 是否为 | 质押 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 一大股 | 数量 | 持股份 | 股本 | 限售股 | 补充 | 起始日 | 质押 到期日 | 质权人 | 质押 用途 | | ...

证券代码：301093 证券简称：华兰股份 公告编号：2026-008 江苏华兰药用新材料股份有限公司 关于开立募集资金现金管理产品专用结算账户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 二、投资风险及风险控制措施 （一）投资风险 1、尽管公司及子公司拟使用闲置募集资金投资的品种为安全性高、流动性 好的投资产品，但金融市场受宏观经济的影响较大，不排除该项投资受到市场波 动的影响； 2、公司及子公司将根据经济形势以及金融市场的变化适时适量的介入，因 此短期投资的实际收益难以可靠预计。 江苏华兰药用新材料股份有限公司（以下简称"公司"）于 2025 年 11 月 28 日召开第六届董事会第八次会议，审议通过了《关于使用部分闲置募集资金和自 有资金进行现金管理的议案》。上述议案已经公司于 2025 年 12 月 17 日召开的 2025 年第六次临时股东会审议通过，同意公司及子公司使用不超过人民币 110,000 万元的闲置募集资金（含超募资金，下同）和自有资金进行现金管理， 其中募集资金不超过 80,000 万元、自有资金不超过 30,000 万元。现 ...

创业板医疗（970082）指数十大成份股详情如下： 证券之星消息，1月23日，创业板医疗（970082）指数报收于4022.47点，涨1.62%，成交210.38亿元， 换手率2.5%。当日该指数成份股中，上涨的有46家，华兰股份以12.8%的涨幅领涨，下跌的有3家，新 产业以0.99%的跌幅领跌。 资金流向方面，创业板医疗（970082）指数成份股当日主力资金净流入合计10.42亿元，游资资金净流 出合计3729.45万元，散户资金净流出合计10.05亿元。成份股资金流向详情见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Market Performance - The medical device sector increased by 1.64% on January 23, with Hualan Biological leading the gains [1] - The Shanghai Composite Index closed at 4136.16, up 0.33%, while the Shenzhen Component Index closed at 14439.66, up 0.79% [1] Top Gainers in Medical Device Sector - Hualan Biological (301093) closed at 84.35, up 12.80%, with a trading volume of 137,500 shares and a transaction value of 1.117 billion [1] - Kangzhong Medical (688607) closed at 66.69, up 8.33%, with a trading volume of 41,500 shares [1] - Xishan Technology (688576) closed at 80.36, up 7.43%, with a trading volume of 28,300 shares [1] - Other notable gainers include Sanyou Medical (688085) and BGI Genomics (688114) with increases of 6.24% and 5.73% respectively [1] Market Capital Flow - The medical device sector saw a net inflow of 581 million in main funds, while retail investors experienced a net outflow of 373 million [2][3] - The main funds showed significant interest in Meihua Medical (301363) with a net inflow of 1.73 billion, representing 17.84% of its total [3] - Other companies like Mindray Medical (300760) and Union Medical (688271) also attracted main fund inflows, while experiencing retail outflows [3]

Core Viewpoint - Hualan Co., Ltd. is actively increasing its investment in the AI pharmaceutical sector by injecting 450 million yuan into its wholly-owned subsidiary, Hainan Lingqing Intelligent Pharmaceutical Technology Co., Ltd., raising its registered capital from 50 million yuan to 500 million yuan, indicating a strong commitment to AI-driven drug development [1][2] Group 1: Investment and Strategic Intent - The capital increase aims to enhance the financial strength of Lingqing Intelligent, which is crucial for its business development and talent acquisition during a key phase of its operational setup [1][2] - This move is part of Hualan's broader strategy to solidify its position in the rapidly evolving AI pharmaceutical industry, which requires significant capital and resource integration capabilities [1][2] Group 2: Market Trends and Industry Context - The AI pharmaceutical market is projected to grow from 11.9 billion USD in 2023 to 74.6 billion USD by 2032, with a compound annual growth rate of 22.6%, highlighting the industry's potential for disruption and innovation [3] - Recent collaborations, such as NVIDIA's partnership with Eli Lilly to invest 1 billion USD in an AI innovation lab, underscore the increasing focus on AI solutions to address long-standing challenges in the pharmaceutical sector [2][3] Group 3: Company Developments and Future Outlook - Hualan has established Lingqing Intelligent as a strategic platform for AI pharmaceutical initiatives, with previous investments and the formation of an expert committee to guide its efforts [3] - The company's ongoing commitment to AI in drug development positions it favorably to capitalize on emerging opportunities in the industry, potentially creating long-term value for shareholders [3]